Ron Lanton Discusses Proposed COINS Act Restrictions on Biotechnology Transactions with Fierce Biotech

Ron Lanton III spoke with Fierce Biotech's Angus Liu about proposed COINS Act restrictions on China-related biotechnology transactions, including pharmaceutical licensing, joint ventures, venture capital investment, and the legal uncertainties facing U.S. biotechnology companies.